Prognostic implications of histological tumor regression (Böhm's score) in patients receiving neoadjuvant chemotherapy for high grade serous tubal & ovarian carcinoma
HPV and Gynecologic Cancer
Related content
HPV and Gynecologic Cancer
Prognostic significance of Ki-67 levels and hormone receptor expression in low-grade serous ovarian carcinoma: an investigation of the tumor bank ovarian cancer network
Hum Pathol.
Sehouli J, Braicu EI, Richter R, Denkert C, Jank P, Jurmeister PS, Kunze CA, Budczies J, Darb-Esfahani S, Schmitt WD, Traut A, Grabowski J, Taube E, Plett H
doi: 10.1016/j.humpath.
RECOMMENDED
Uro-Oncology
Updated Results of PURE-01 with Preliminary Activity of Neoadjuvant Pembrolizumab in Patients with Muscle-invasive Bladder Carcinoma with Variant Histologies
★ 2
Recommended by
Prof. Dr Richard Cathomas, Faculty Member
Eur Urol.
Necchi A, Raggi D, Gallina A, Madison R, Colecchia M, Lucianò R, Montironi R, Giannatempo P, Farè E, Pederzoli F, Bandini M, Bianchi M, Colombo R, Gandaglia G, Fossati N, Marandino L, Capitanio U, Dehò F, Ali SM, Chung JH, Ross JS, Salonia A, Briganti A, Montorsi F
doi: 10.1016/j.eururo.2019.10.026.
HPV and Gynecologic Cancer
Preoperative predictors of delay in initiation of adjuvant chemotherapy in patients undergoing primary debulking surgery for ovarian cancer
Gynecol Oncol.
Singh S, Guetzko M, Resnick K
doi: 10.1016/j.ygyno.
HPV and Gynecologic Cancer
Chemotherapy alone for patients 75 years and older with epithelial ovarian cancer - is interval cytoreductive surgery still needed?
Am J Obstet Gynecol.
Klein DA, Mann AK, Freeman AH, Liao CI, Kapp DS, Chan JK
doi: 10.1016/j.ajog.2019.07.050.
HPV and Gynecologic Cancer
The prognostic value of residual disease after neoadjuvant chemotherapy in advanced ovarian cancer; A systematic review
Gynecol Oncol.
Timmermans M, van der Hel O, Sonke GS, Van de Vijver KK, van der Aa MA, Kruitwagen RF
doi: 10.1016/j.ygyno.2019.02.019.
Uro-Oncology
The Probability of Aggressive Versus Indolent Histology Based on Renal Tumor Size: Implications for Surveillance and Treatment
Eur Urol.
Bhindi B, Thompson RH, Lohse CM, Mason RJ, Frank I, Costello BA, Potretzke AM, Hartman RP, Potretzke TA, Boorjian SA, Cheville JC, Leibovich BC
doi: 10.1016/j.eururo.2018.06.003.
HPV and Gynecologic Cancer
Preexisting TP53-Variant Clonal Hematopoiesis and Risk of Secondary Myeloid Neoplasms in Patients With High-grade Ovarian Cancer Treated With Rucaparib
JAMA Oncol
Kwan TT, Oza AM, Tinker AV, Ray-Coquard I, Oaknin A, Aghajanian C, Lorusso D, Colombo N, Dean A, Weberpals J, Severson E, Vo LT, Goble S, Maloney L, Harding T, Kaufmann SH, Ledermann JA, Coleman RL, McNeish IA, Lin KK, Swisher EM
doi: 10.1001/jamaoncol.2021.4664
HPV and Gynecologic Cancer
Chemotherapy with or without avelumab followed by avelumab maintenance versus chemotherapy alone in patients with previously untreated epithelial ovarian cancer (JAVELIN Ovarian 100): an open-label, randomised, phase 3 trial
Lancet Oncol
Monk BJ, Colombo N, Oza AM, Fujiwara K, Birrer MJ, Randall L, Poddubskaya EV, Scambia G, Shparyk YV, Lim MC, Bhoola SM, Sohn J, Yonemori K, Stewart RA, Zhang X, Perkins Smith J, Linn C, Ledermann JA
doi: 10.1016/S1470-2045(21)00342-9
Overactive Bladder
Optimization of Patient Selection for Neoadjuvant Chemotherapy in Muscle-invasive Urothelial Carcinoma of the Bladder
Clin Genitourin Cancer.
Hensley PJ, Goodwin J, Davenport DL, Strup SE, James A
doi: 10.1016/j.clgc.2018.02.007.